Last updated: May 29, 2026
Executive summary
- Sodium tetradecyl sulfate (STS) suppliers typically sell either (1) the API/bulk drug substance for compounding and injectable manufacturing, or (2) finished injectable products sourced from branded manufacturers and specialty injectables makers.
- The supplier landscape is dominated by chemical manufacturers for bulk material and contract-manufacturing/formulation partners for injectable presentations.
- The exact supplier list for STS depends on whether the need is API grade (for manufacturing) or commercially packaged injectable product (for direct clinical use).
Which companies supply sodium tetradecyl sulfate API (bulk drug substance)?
Most procurement of STS starts with API/bulk material produced as a specialty organic chemical, then validated for pharmaceutical use via supplier documentation (CoA, impurity profile, residual solvents, particle size where relevant, and a controlled specification suitable for sterile injectable manufacture).
Common supplier archetypes for STS bulk
- Specialty chemical manufacturers with pharmaceutical-grade product lines
- API distributors that repackage chemical manufacturers’ STS into logistics-ready inventory
- Contract chemical manufacturers (CMOs) that produce STS under quality agreements for injectable programs
What specifications buyers usually require for injectable manufacture
- Defined assay and sulfated/related impurity limits
- Trace heavy metals and controlled loss on drying
- Polymerizable/oxidizable impurities control (process dependent)
- Residual solvents and water content controls suitable for parenteral formulation compatibility
Who supplies sodium tetradecyl sulfate injectable products for sclerotherapy?
Clinically, STS is used as a sclerosant in vascular disorders (for example, varicose veins and related indications depending on jurisdiction). In practice, hospitals and clinics source via finished-dose channels through tendering, hospital pharmacy supply chains, and authorized distributors.
Sourcing pathways for finished STS
- Authorized distributors of locally registered injectable STS products
- Tender-based procurement for hospital formularies
- Imports through licensed pharmaceutical wholesalers when locally registered products are limited
Buyer-facing documentation for hospital procurement
- GMP manufacturer details
- Lot-specific CoA and sterility-related batch documentation where applicable
- Shelf-life, storage conditions, and reconstitution/administration notes per label
What Orange Book status applies to sodium tetradecyl sulfate products?
STS is not widely positioned as a modern US “blockbuster” small-molecule with a consolidated Orange Book ecosystem comparable to current major therapeutics. Where STS injectable products are marketed in the US, they may have listings tied to specific NDA/ANDA entries and historic approvals, and the Orange Book reflects those exact NDA/ANDA-labeled products rather than the ingredient broadly.
How to interpret “Orange Book status” for a chemical sclerosant
- Exclusivity and patent protection attach to specific approved products, not the generic ingredient alone
- Patent listings are tied to an NDA/ANDA record for the labeled strength and dosage form
What patents protect sodium tetradecyl sulfate injectable products (and do they affect supplier access)?
Whether supplier access is constrained by IP depends on the specific approved formulation, concentration, container/closure system, and manufacturing process tied to an NDA/ANDA record.
How IP typically maps to supplier constraints
- Formulation process patents can limit access to injectable-ready material even if bulk STS is available
- Method-of-use patents, where present, can restrict label claims but do not always block manufacturing of the active ingredient itself
- Container-closure and sterilization method patents can constrain direct formulation transfer
Why supplier lists often differ by end-use
- API procurement can be easier when no formulation-level IP binds the injectable product supply chain
- Finished injectable product procurement can be constrained by registered manufacturing, packaging, and sterile validation requirements
When does sodium tetradecyl sulfate lose exclusivity and when can generics enter?
Generic entry timing is driven by the underlying NDA/ANDA records, patent expirations, and exclusivity (market exclusivity, pediatric exclusivity, and other program-based exclusivity) as applicable to the specific US product.
Key timing drivers
- Patent expiration for listed drug-product patents
- Statutory exclusivity periods attached to the NDA
- Any Paragraph IV challenges filed against the reference product’s listed patents (if present in the record)
What this means for supplier selection
- If the target is API for manufacturing, timing is less relevant than regulatory status of the finished drug
- If the target is finished injectable supply, market access is tied to the product’s regulatory and exclusory landscape
Which companies challenge sodium tetradecyl sulfate patents via Paragraph IV?
Paragraph IV activity depends on the existence of ANDAs for STS injectables with Orange Book-listed patents. The supplier landscape and litigation landscape are product-specific.
How to map challenges to supplier risk
- If Paragraph IV challenges exist, they usually identify both the generic filer (potential supplier) and the reference NDA sponsor
- Litigation outcomes can determine settlement-driven entry dates for the generic product and shape which suppliers win market access
What manufacturing/IP barriers affect sodium tetradecyl sulfate injection supply?
Even when bulk STS is commercially available, injectable supply can face practical barriers.
Key barriers
- Sterile filtration/aseptic processing validation for the finished injectable solution/emulsion form
- Endotoxin controls and parenteral-grade water and excipient specifications
- Container-closure compatibility and stability testing
- Batch-to-batch impurity profiling aligned with validated dissolution and assay methods
How does sodium tetradecyl sulfate API pricing and supply reliability compare across suppliers?
Pricing and supply reliability usually diverge based on:
- Whether the supplier offers pharmaceutical-grade specifications versus commodity-grade chemical
- Whether the supplier can support sterile injectable-grade documentation and validated impurity control
- Lead times and batch size economics
What to request in supplier qualification
- Certificates of analysis for multiple recent lots
- Full specification sheet and change-control policy
- Manufacturing site GMP status and quality agreements readiness
- Stability data for STS in relevant formulation matrices (for finished product manufacturers)
What delivery systems and strengths exist for sodium tetradecyl sulfate, and do those change the supplier list?
Supplier lists often change with dosage form and strength because formulation and packaging needs differ.
Strength and presentation effects
- Different concentrations and labeled strengths require separate formulation validation and can constrain which suppliers can support sterile manufacture
- Packaging format (vials versus prefilled systems) affects container-closure compatibility and finished goods logistics
Commercial landscape: which supplier segments dominate sodium tetradecyl sulfate availability?
STS availability tends to be split into:
- API supply segment: chemical makers and API distributors
- Finished product segment: injectable manufacturers and specialty injectables brands/distributors
Where supply tends to concentrate
- Bulk API is supplied by chemical manufacturers with pharmaceutical-grade documentation capabilities
- Finished injectables are supplied by manufacturers with sterile manufacturing capability and local regulatory approvals
Key takeaways
- Sodium tetradecyl sulfate is sourced through two practical channels: API/bulk chemical procurement and finished injectable product distribution.
- Supplier selection is product-form and regulatory-driven, not just chemical availability.
- For injectable programs, the critical differentiator is pharmaceutical-grade documentation and sterile-injection readiness (quality system, impurity control, validation support).
- IP and exclusivity, where applicable, constrain finished product market access on a record-by-record basis rather than across the ingredient globally.
FAQs
- How do I identify pharmaceutical-grade suppliers for sodium tetradecyl sulfate API vs commodity chemical suppliers?
- What documentation is required for sodium tetradecyl sulfate to support injectable manufacturing qualification (CoA, impurity profile, residual solvents)?
- Do formulation patents for sodium tetradecyl sulfate affect access to bulk API suppliers?
- How do local registrations and distributor networks influence sodium tetradecyl sulfate injectable availability by country?
- What common quality failures occur in sodium tetradecyl sulfate batches supplied for parenteral use (assay, impurities, endotoxins)?
References (APA)
- United States Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Drug Approval and the Orange Book (background on how product listings and patents work). FDA. https://www.fda.gov/
